Alpha 2.0
Login Register
» Articles » PMID: 21300093

Vaccination with the Defined Chlamydial Secreted Protein CPAF Induces Robust Protection Against Female Infertility Following Repeated Genital Chlamydial Challenge

Overview
Journal Vaccine
Specialty Allergy & Immunology
Date 2011 Feb 9
PMID 21300093
Citations 31
Authors
Ashlesh K Murthy
Weidang Li
M Neal Guentzel
Guangming Zhong
Bernard P Arulanandam
Affiliations
Soon will be listed here.
Abstract

We previously have shown the efficacy of recombinant (r) chlamydial protease-like activity factor (CPAF) vaccination against hydrosalpinx development following primary genital chlamydial challenge. In this study, we evaluated further the protection induced by rCPAF vaccination against infertility. Following primary challenge, fertility levels were not significantly different between the mock- and CPAF-vaccinated and Chlamydia alone challenged mice. However, following secondary genital chlamydial challenge, mock (PBS) immunized mice displayed a significant reduction of fertility compared to age-matched naïve mice, while mice vaccinated intranasally with rCPAF+CpG displayed significant prevention of infertility. These results suggest that hydrosalpinx may be a reliable indicator of impending infertility, and that rCPAF is a promising candidate to prevent infertility resulting from repeated genital chlamydial infections.

Citing Articles

Immunity to Sexually Transmitted Bacterial Infections of the Female Genital Tract: Toward Effective Vaccines.

Yount K, Darville T Vaccines (Basel). 2024; 12(8).

PMID: 39203989 PMC: 11359697. DOI: 10.3390/vaccines12080863.

Structural Assessment of Major Outer Membrane Protein (MOMP)-Derived Vaccine Antigens and Immunological Profiling in Mice with Different Genetic Backgrounds.

Roe S, Zhu T, Slepenkin A, Berges A, Fairman J, de la Maza L Vaccines (Basel). 2024; 12(7).

PMID: 39066427 PMC: 11281497. DOI: 10.3390/vaccines12070789.

Protective anti-chlamydial vaccine regimen-induced CD4+ T cell response mediates early inhibition of pathogenic CD8+ T cell response following genital challenge.

Murthy A, Wright-McAfee E, Warda K, Moy L, Bui N, Musunuri T Pathog Dis. 2024; 82.

PMID: 38684476 PMC: 11149721. DOI: 10.1093/femspd/ftae008.

Evaluation of three formulations based on Polymorphic membrane protein D in mice infected with .

Russi R, Del Balzo D, Reidel I, Alonso Bivou M, Flor N, Lujan A Front Immunol. 2023; 14:1267684.

PMID: 38045697 PMC: 10690417. DOI: 10.3389/fimmu.2023.1267684.

Preclinical screen for protection efficacy of chlamydial antigens that are immunogenic in humans.

Lu C, Wang J, Zhong G Infect Immun. 2023; 91(11):e0034923.

PMID: 37889004 PMC: 10652899. DOI: 10.1128/iai.00349-23.

References
1.
Murthy A, Chambers J, Meier P, Zhong G, Arulanandam B . Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect Immun. 2006; 75(2):666-76. PMC: 1828486. DOI: 10.1128/IAI.01280-06. View
2.
Chaganty B, Murthy A, Evani S, Li W, Guentzel M, Chambers J . Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. Vaccine. 2010; 28(11):2323-9. PMC: 2846592. DOI: 10.1016/j.vaccine.2009.12.064. View
3.
Dong F, Zhong Y, Arulanandam B, Zhong G . Production of a proteolytically active protein, chlamydial protease/proteasome-like activity factor, by five different Chlamydia species. Infect Immun. 2005; 73(3):1868-72. PMC: 1064953. DOI: 10.1128/IAI.73.3.1868-1872.2005. View
4.
Cong Y, Jupelli M, Guentzel M, Zhong G, Murthy A, Arulanandam B . Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Vaccine. 2007; 25(19):3773-80. PMC: 2757645. DOI: 10.1016/j.vaccine.2007.02.010. View
5.
Murphey C, Murthy A, Meier P, Guentzel M, Zhong G, Arulanandam B . The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells. Cell Immunol. 2006; 242(2):110-7. PMC: 1885537. DOI: 10.1016/j.cellimm.2006.10.002. View